Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Li, Yuqing ^a   Li, Yi ^a   Wedrén, Sara ^b   Li, Guoliang ^a   Charn, Tze Howe ^a   Desai, Kartiki Vasant ^a   Bonnard, Carine ^c   Czene, Kamila ^b   Humphreys, Keith ^b   Darabi, Hatef ^b   Einarsdóttir, Kristjana ^d   Heikkinen, Tuomas ^e   Aittomäki, Kristiina ^e   Blomqvist, Carl ^e   Chia, Kee Seng ^f   Nevanlinna, Heli ^e   Hall, Per ^b   Liu, Edison T ^a   Liu, Jianjun ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; RNA POLYMERASE II; CARRIER PROTEIN; ESTROGEN RECEPTOR ALPHA, HUMAN; PPARGC1B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PREVENTION; CELL STRAIN MCF 7; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FINLAND; GENE EXPRESSION REGULATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; RECEPTOR OCCUPANCY; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; UPREGULATION; BREAST TUMOR; CASE CONTROL STUDY; EPISTASIS; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; RISK ASSESSMENT;

AGED; BREAST NEOPLASMS; CARRIER PROTEINS; CASE-CONTROL STUDIES; EPISTASIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; FINLAND; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; SWEDEN; TRANSCRIPTION, GENETIC;

EID: 84860390629     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2817     Document Type: Article

References (48)

1. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
2. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004, 96:1856-1865. 10.1093/jnci/djh336, 15601642.
3. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000, 27:135-145.
4. Gao X, Loggie BW, Nawaz Z. The roles of sex steroid receptor coregulators in cancer. Mol Cancer 2002, 1:7.
5. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004, 25:45-71. 10.1210/er.2003-0023, 14769827.
6. Tremblay GB, Giguere V. Coregulators of estrogen receptor action. Crit Rev Eukaryot Gene Expr 2002, 12:1-22. 10.1615/CritRevEukaryotGeneExpr.v12.i1.10, 12433063.
7. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23:1616-1622. 10.1200/JCO.2005.10.036, 15755967.
8. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:1979-1987. 10.1158/1078-0432.CCR-09-1823, 20332324.
9. Einarsdottir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjolander A, Czene K, Wedren S, Liu ET, Hall P, Humphreys K, Liu J. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008, 10:R15. 10.1186/bcr1861, 2374971, 18271972.
10. Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, Rodriguez R, Barbosa-Morais NL, Ponder BA, Low YL, Bingham S, Haiman CA, Le Marchand L, Broeks A, Schmidt MK, Hopper J, Southey M, Beckmann MW, Fasching PA, Peto J, Johnson N, Bojesen SE, Nordestgaard B, Milne RL, Benitez J, Hamann U, Ko Y, Schmutzler RK, Burwinkel B, Schurmann P, et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009, 18:1131-1139. 10.1093/hmg/ddn429, 2722230, 19126777.
11. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009, 41:324-328. 10.1038/ng.318, 2754845, 19219042.
12. Burwinkel B, Wirtenberger M, Klaes R, Schmutzler RK, Grzybowska E, Forsti A, Frank B, Bermejo JL, Bugert P, Wappenschmidt B, Butkiewicz D, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Bartram CR, Hemminki K. Association of NCOA3 polymorphisms with breast cancer risk. Clin Cancer Res 2005, 11:2169-2174. 10.1158/1078-0432.CCR-04-1621, 15788663.
13. Ceschi M, Sun CL, Van Den Berg D, Koh WP, Yu MC, Probst-Hensch N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 2005, 26:1457-1464. 10.1093/carcin/bgi093, 15845652.
14. Haiman CA, Garcia RR, Hsu C, Xia L, Ha H, Sheng X, Le Marchand L, Kolonel LN, Henderson BE, Stallcup MR, Greene GL, Press MF. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer 2009, 9:43. 10.1186/1471-2407-9-43, 2637888, 19183483.
15. Montgomery KG, Chang JH, Gertig DM, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG. The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women. Breast Cancer Res 2005, 7:R353-R356. 10.1186/bcr1009, 1143559, 15987430.
16. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005, 5:343-357. 10.1124/mi.5.6.7, 16394250.
17. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999, 20:321-344. 10.1210/er.20.3.321, 10368774.
18. Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, Persson I, Baron J, Weiderpass E. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004, 6:R437-R449. 10.1186/bcr811, 468663, 15217512.
19. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkila P, Sauter G, Kallioniemi OP, Bartek J, Nevanlinna H. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005, 113:575-580. 10.1002/ijc.20638, 15472904.
20. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000, 92:1529-1531. 10.1093/jnci/92.18.1529, 10995809.
21. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853. 10.1038/ng.155, 18511948.
22. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438. 10.1086/341943, 379177, 12094328.
23. Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H. Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients?. Eur J Cancer 2000, 36:1143-1148. 10.1016/S0959-8049(00)00093-9, 10854948.
24. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999, 81:339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6, 10209946.
25. Magnusson C, Colditz G, Rosner B, Bergstrom R, Persson I. Association of family history and other risk factors with breast cancer risk (Sweden). Cancer Causes Control 1998, 9:259-267. 10.1023/A:1008817018942, 9684706.
26. Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R, Adami HO. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer 1999, 80:231-236. 10.1002/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.0.CO;2-R, 9935204.
27. The International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320. 10.1038/nature04226, 1880871, 16255080, The International HapMap Consortium.
28. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004, 74:106-120. 10.1086/381000, 1181897, 14681826.
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265. 10.1093/bioinformatics/bth457, 15297300.
30. Liu J, Vasant DK, Li Y, Banu S, Lee YK, Qu D, Heikkinen T, Aaltonen K, Muranen TA, Kajiji TS, Bonnard C, Aittomäki K, von Smitten K, Blomqvist C, Hopper JL, Southey MC, Brauch H, Consortium TG, Chenevix-Trench G, Beesley J, Spurdle AB, Chen X, Czene K, Hall P, Nevanlinna H, Liu ET. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer AOCSG Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development. HUGO J 2009, 3:31-40. 10.1007/s11568-010-9138-x, 2882646, 21119756, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer AOCSG.
31. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000, 365-386. Totowa, NJ: Humana Press, Krawetz S, Misener S.
32. Li Y, Sung WK, Liu JJ. Association mapping via regularized regression analysis of single-nucleotide-polymorphism haplotypes in variable-sized sliding windows. Am J Hum Genet 2007, 80:705-715. 10.1086/513205, 1852711, 17357076.
33. Kressler D, Hock MB, Kralli A. Coactivators PGC-1β and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator tamoxifen. J Biol Chem 2007, 282:26897-26907. 10.1074/jbc.M705596200, 17631495.
34. Kressler D, Schreiber SN, Knutti D, Kralli A. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem 2002, 277:13918-13925. 10.1074/jbc.M201134200, 11854298.
35. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64. 10.1038/nature08497, 2774924, 19890323.
36. Li G, Fullwood MJ, Xu H, Mulawadi FH, Velkov S, Vega V, Ariyaratne PN, Mohamed YB, Ooi HS, Tennakoon C, Wei CL, Ruan Y, Sung WK. ChIA-PET tool for comprehensive chromatin interaction analysis with paired-end tag sequencing. Genome Biol 2010, 11:R22. 10.1186/gb-2010-11-2-r22, 2872882, 20181287.
37. Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis IL, Blomqvist C, Nevanlinna H, Ozcelik H. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 2008, 8:6. 10.1186/1471-2407-8-6, 2254632, 18194538.
38. Yu CP, Yu JC, Sun CA, Tzao C, Ho JY, Yen AM. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 2008, 107:95-102. 10.1007/s10549-007-9522-y, 18043898.
39. Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer JP, Ponder BA, Easton DF, Pharoah PD, Dunning AM. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 2008, 29:333-341. 10.1093/carcin/bgm284, 2346546, 18174243.
40. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Weitzer W, Leithner A, Samonigg H. The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 2003, 82:165-168. 10.1023/B:BREA.0000004372.20461.33, 14703063.
41. Wirtenberger M, Tchatchou S, Hemminki K, Schmutzhard J, Sutter C, Schmutzler RK, Meindl A, Wappenschmidt B, Kiechle M, Arnold N, Weber BH, Niederacher D, Bartram CR, Burwinkel B. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis 2006, 27:2201-2208. 10.1093/carcin/bgl067, 16704985.
42. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E, Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008, 40:703-706. 10.1038/ng.131, 18438407.
43. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007, 39:865-869. 10.1038/ng2064, 17529974.
44. Milne RL, Benitez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schurmann P, Bremer M, Hillemanns P, Dork T, Devilee P, van Asperen CJ, et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 2009, 101:1012-1018. 10.1093/jnci/djp167, 2724850, 19567422.
45. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000054. 10.1371/journal.pgen.1000054, 2291027, 18437204.
46. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004, 13:1558-1568.
47. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008, 14:8000-8009. 10.1158/1078-0432.CCR-08-0975, 2668137, 19088016.
48. Low YL, Li Y, Humphreys K, Thalamuthu A, Darabi H, Wedren S, Bonnard C, Czene K, Iles MM, Heikkinen T, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Liu ET, Liu J. Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet 2010, 6:e1001012. 10.1371/journal.pgen.1001012, 2895650, 20617168.